###begin article-title 0
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 555 559 <span type="species:ncbi:10090">mice</span>
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-binding protein that participates in the regulation of DNA repair and maintenance of genomic integrity. In addition, PARP-1 has a role in several models of inflammation disease, where its absence or inactivation confers protection. The aim of this study was to analyze the impact of selective PARP-1 suppression in collagen antibody-induced arthritis. We show that PARP-1 deficiency partially reduces the severity of arthritis, although the incidence of disease was similar in control and deficient mice. Decreased clinical scores were accompanied by partial reduction of histopathological findings. Interestingly, quantitative real-time PCR and ELISA analysis revealed that the absence of PARP-1 down-regulated IL-1beta and monocyte chemotactic protein 1 expression in arthritic joints whereas tumor necrosis factor-alpha transcription was not impaired. Our results provide evidence of the contribution of PARP-1 to the progression of arthritis and identify this protein as a potential therapeutic target for the treatment of rheumatoid arthritis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 714 715 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Rheumatoid arthritis (RA) is characterized by inflammation, synovial hyperplasia, pannus formation and progressive destruction of cartilage and bone [1,2]. In RA, inflammatory cytokines, chemokines, growth factors and adhesion molecules are produced by leukocytes and resident synoviocytes. These factors perpetuate chronic inflammation by the recruitment of additional inflammatory cells into the sublining region that, in turn, lead to continuous production of inflammatory mediators and enzymes, resulting in destruction of joint structures [3-8]. The efficacy of treatments with tumor necrosis factor (TNF) and IL-1 inhibitors strongly support the key role of inflammatory cytokines in the pathogenesis of RA [9,10] and points to therapeutic approaches directed toward regulation of cytokine networks involved in RA.
###end p 4
###begin p 5
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1202 1210 1202 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1214 1223 1214 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1339 1341 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1342 1344 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1345 1347 1341 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1653 1655 1645 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1787 1789 1775 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1957 1959 1945 1947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1960 1962 1948 1950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
Poly(ADP-ribose) polymerase (PARP)-1 is a highly conserved nuclear zinc-finger protein involved in maintenance of genomic integrity. PARP-1 detects DNA breakage generated by several genotoxic agents and synthesizes and transfers ADP ribose units (poly(ADPribosyl)ation activity) into acceptor proteins involved in the conservation of chromatin structure and DNA metabolism, modulating in this way DNA repair and cell survival [11,12]. Studies with PARP-1 deficient mice or with chemical inhibitors have enlarged the physiological role of this protein. In these situations, lack of PARP-1 function protects against several disorders with an inflammatory component, such as endotoxic shock [13], streptozotocin induced diabetes [14], chronic colitis [15] and uveitis [16]. Two mechanisms have been proposed to explain the role of PARP-1 in these diseases. One mechanism is related to massive PARP-1 activation induced by genotoxic injury developed during the inflammatory process. In this case, hyperactivated PARP-1 would lead to ATP depletion and cell dysfunction [17]. The other proposed mechanism is related to a functional link between PARP-1 and inflammation-related transcription factors. Several in vivo and in vitro studies have demonstrated the involvement of PARP-1 in the transcriptional activation of nuclear factor (NF)kappaB [13,18,19], but the proposed mechanisms are contradictory. There is evidence for mechanisms that are both dependent on and independent of auto-poly(ADP-ribosyl)ation function. In the first case, NFkappaB would be blocked by binding to PARP-1 and this union would be disrupted by PARP-1 auto-poly(ADP-ribosyl)ation [18]. In the second case, PARP-1 would act as a transcriptional co-activator in the binding of NFkappaB with its target DNA sequences [19]. Recently, it has also been reported that PARP-1 regulates other transcription factors implicated in stress/inflammation, such as AP-1, Oct-1, SP-1, YY-1 and Stat-1 [20,21]. Thus, in addition to its involvement in genome surveillance, PARP-1 appears to have a key role in inflammatory responses.
###end p 5
###begin p 6
###xml 162 166 <span type="species:ncbi:10090">mice</span>
Here we report the impact of selective PARP-1 suppression on the collagen antibody-induced arthritis model (CAIA). This model, induced by passive immunization of mice with anti-type II collagen antibodies, allows the study of the effector phase of arthritis, where PARP-1 might be involved. We have found that the absence of PARP-1 partially reduced the severity of arthritis, likely by the impairment of IL-1beta and monocyte chemotactic protein (MCP)-1 transcription in arthritic tissue. These results provide support for the contribution of PARP-1 in the progression of arthritis and open the possibility that specific inhibitors might become therapeutic tools in RA.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 8
###begin p 9
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 243 247 243 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 282 288 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 293 299 293 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 299 303 299 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 313 317 313 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 323 329 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Parp-1</italic>
###xml 329 333 329 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 377 380 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 388 391 388 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
Mice lacking PARP-1 (kindly provided by G de Murcia, CNRS, Strasbourg, France) have been described previously [22]. The mice used in these experiments were of mixed (C57BL/6 x 129Sv) background. More than ten different breeding pairs of parp-1+/o mice were intercrossed to generate parp-1+/+, parp-1+/o and parp-1o/o mice. Parp-1o/o mice and control matched littermates (parp-1+/+, parp-1+/o) were analyzed.
###end p 9
###begin p 10
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Genotypes were assessed by PCR of tail DNA. The mice were maintained in the mouse facility of the Facultad de Medicina de Santiago de Compostela. Animal care was in compliance with Spanish regulations on the protection of animals used for experimental and other scientific purposes (Real Decreto 223/1998). The experimental protocols were approved by the Animal Care and Use Committee of the University of Santiago de Compostela.
###end p 10
###begin title 11
Collagen antibody-induced arthritis (CAIA) and clinical scoring
###end title 11
###begin p 12
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 690 695 <span type="species:ncbi:10090">mouse</span>
CAIA was induced in 6-week-old male and female mice by intravenous injection on day 0 of 3 mg/mouse of an arthritogenic cocktail of 4 monoclonal anti-type II collagen antibodies (Arthrogen, Chondrex, Redmond, WA, USA) [23]. On day 2, mice were boosted with 50 mug of lipopolysaccharide by intraperitoneal injection. Arthritis was assessed every other day by two blinded observers until day 12, using a semi-quantitative clinical score ranging from 0 to 4: 0, no swelling; 1, slight swelling and erythema of the ankle, wrist or digits; 2, moderate swelling and erythema; 3, severe swelling and erythema; and 4, maximal inflammation with joint rigidity. The maximum possible score was 16 per mouse.
###end p 12
###begin title 13
Histological analysis
###end title 13
###begin p 14
Hind limbs were prepared for histology by dissecting the skin and muscle, and then sectioning knee joints. Specimens were fixed for 24 hours and demineralized in phosphate-buffered saline-0.5 M EDTA for 10 days. Knee joints were embedded in paraffin and sections were cut and stained with hematoxylin and eosin (H&E) for evaluation of inflammation. For analysis of damage to cartilage, knee sections were stained with Toluidine blue, Safranin-O and Masson trichrome following standard methodology. The sections were scored by two blinded observers. Synovial inflammation was scored on a scale of 0 to 3: 0, no inflammation; 1, slight thickening of synovial cell layer and/or some inflammatory cells in the sublining; 2, thickening of synovial lining, infiltration of the sublining; and 3, pannus formation.
###end p 14
###begin p 15
Exudate was scored according to the following scale: 0, no detectable neutrophil infiltration in the synovial space; 1, mild infiltration; 2, moderate infiltration; and 3, severe infiltration.
###end p 15
###begin p 16
Cartilage damage was evaluated following a scale of 0 to 3: 0, normal cartilage; 1, cartilage surface irregularities and loss of metachromasia adjacent to superficial chondrocytes; 2, fibrillation of cartilage and formation of some chondrocyte clusters, with minor loss of surface cartilage; and 3, gross cartilage abnormalities, including loss of superficial cartilage, extension of fissures close to subchondral bone, and a large number of chondrocyte clusters.
###end p 16
###begin title 17
Fibroblast like synoviocytes
###end title 17
###begin p 18
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 72 76 72 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 86 90 86 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 531 533 525 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
Fibroblast-like synoviocytes (FLSs) were isolated from parp-1+/+, parp-1+/o and parp-1o/o mice. Synovial tissue was minced and incubated with 1 mg/ml collagenase in serum-free DMEM (Gibco, Invitrogen, Barcelona, Spain) for 3 hours at 37degreesC. After digestion, FLSs were filtered trough a nylon cell strainer (BD Falcon, Franklin Lakes, NJ, USA), washed extensively, and cultured in DMEM supplemented with 10% v/v FCS (Gibco, Invitrogen), penicillin, streptomycin, and L-glutamine (Sigma, St Louis, MO, USA) in a humidified 5% CO2 atmosphere. After overnight culture, non-adherent cells were removed, and adherent cells were cultured in DMEM supplemented with 10% v/v FCS.
###end p 18
###begin title 19
Western blot analysis
###end title 19
###begin p 20
###xml 294 296 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 332 336 <span type="species:ncbi:9925">goat</span>
###xml 342 348 <span type="species:ncbi:9986">rabbit</span>
###xml 349 360 <span type="species:ncbi:3704">horseradish</span>
Total proteins (20 mug) were separated by 10% SDS-PAGE, transferred to a PVDF membrane (Hybond-P, Amersham Biosciences, Buckinghamshire, UK) and probed with anti-PARP-1 (VIC-5, kindly provided by G de Murcia, CNRS, Strasbourg, France) and anti-actin (Sigma) antibodies as previously described [24]. Bound antibody was revealed with goat anti-rabbit-horseradish peroxidase (Rockland Immunochemicals Inc., Gilbertsville, PA, USA) and the blot was developed using the ECL plus detection system (Amersham Biosciences).
###end p 20
###begin title 21
Quantitative reverse transcription-PCR
###end title 21
###begin p 22
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 44 48 44 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 58 62 58 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 132 136 132 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 146 150 146 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 799 800 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1068 1081 1065 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct</sup>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
Total RNA was obtained from joints of parp-1+/+ and parp-1o/o mice on day 7 following Arthrogen injection, and from joints of parp-1+/+ and parp-1o/o control mice without arthritis. We used the RNeasy Kit and RNase-Free DNase Set (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. One microgram of total RNA was subjected to cDNA synthesis using M-MLV reverse transcriptase, random primers and RNaseOUT recombinant ribonuclease inhibitor (Invitrogen). Quantitative real-time PCR was performed in duplicate in a Chromo-4 real-time thermal cycler (MJ Research, Waltham, MA, USA), using a LightCycler DNA Master SYBR Green I kit (Roche Diagnostics, Barcelona, Spain), according to the manufacturers' protocols. The specific primers used in these reactions are listed in Table 1. Relative levels of gene expression were normalized to the beta-actin gene using the comparative Ct method, where Ct is the cycle at which the amplification is initially detected. The relative amount of mRNA from the different genes was calculated using the formula 2-DeltaDeltaCt, where:
###end p 22
###begin p 23
###xml 18 25 10 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">target </sub>
###xml 29 39 21 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-actin</sub>
###xml 40 64 29 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">WT or KO with arthritis </sub>
###xml 69 76 58 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">target </sub>
###xml 80 90 69 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-actin</sub>
###xml 91 108 77 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">WT or KO controls</sub>
DeltaDeltaCt = [Cttarget - Ctbeta-actin]WT or KO with arthritis - [Cttarget - Ctbeta-actin]WT or KO controls
###end p 23
###begin p 24
###xml 97 99 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">0 </sup>
###xml 181 195 173 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
For wild-type (WT) and PARP-1 deficient samples without arthritis, DeltaDeltaCt equals zero and 20 equals one. For wild-type and knockout (KO) samples with arthritis, the value of 2-DeltaDeltaCt indicates the fold change in gene expression relative to the wild-type and knockout controls, respectively. Melting curves and agarose gel electrophoresis established the purity of the amplified band.
###end p 24
###begin title 25
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Determination of cytokines in mice arthritic knees
###end title 25
###begin p 26
###xml 301 302 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Knee joints were obtained, frozen in liquid nitrogen and homogenized in 0.5 ml ice-cold 20 mM Hepes buffer supplemented with 1 mM dithiothreitol, 0.1% v/v Triton and a protease inhibitor cocktail. After incubation for 30 minutes at 4degreesC, the homogenate was centrifuged for 10 minutes at 10,000 x g. Protein concentration was measured in supernatants by the Bradford method and a volume containing 100 mug of proteins was subjected to ELISA for IL-1beta, TNF-alpha, IL-6 and MCP-1 (OptEIA ELISA Sets, BD Pharmingen), according to the manufacture's instructions.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 90 92 90 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 98 100 98 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Differences between experimental groups were assessed by ANCOVA, MANCOVA and Mann-Whitney U test. p values <0.05 were considered significant.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
PARP-1 protein expression in joint tissue
###end title 30
###begin p 31
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 236 239 236 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 274 277 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o</sup>
###xml 284 291 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1 </italic>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 316 319 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o</sup>
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 416 420 416 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 438 444 438 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 444 448 444 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 564 568 564 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 572 578 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 578 582 578 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 621 626 621 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b, d</xref>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
Although PARP-1 is found in the majority of the nucleated cells of the body, its expression in joint tissue has never been studied. Here, we have analyzed PARP-1 protein expression by western blot in isolated FLSs from wild-type (parp-1+/+) mice, mice lacking PARP-1 (parp-1o/o), and parp-1 heterozygous mice (parp-1+/o). PARP-1 was highly expressed in FLSs from PARP-1 wild-type mice, moderately expressed in parp-1+/o and was absent in parp-1o/o mice (Figure 1a). Comparable results were obtained in the immunohistochemical analysis of joint sections from parp-1+/+ and parp-1o/o mice with anti-PARP-1 antibody (Figure 1b, d).
###end p 31
###begin title 32
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Reduced severity of arthritis in mice lacking PARP-1
###end title 32
###begin p 33
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 188 192 188 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 208 212 208 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 230 234 230 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
To investigate the contribution of PARP-1 to experimental arthritis, we induced CAIA in control and PARP-1 deficient mice (Figure 2a). In eight separate experiments, male and female parp-1+/+ (n = 18), parp-1+/o (n = 8) and parp-1o/o (n = 19) mice were injected with Arthrogen and lipopolysaccharide and monitored for signs of arthritis. Evolution of arthritis was evaluated by two blinded observers on a 0 to 4 scale, as described in Materials and methods.
###end p 33
###begin p 34
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 78 82 78 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 110 112 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 195 199 195 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 491 497 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 497 498 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 512 514 512 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
There was no difference in incidence or clinical course of arthritis in parp-1o/o animals compared with parp-1+ control mice. The incidence of disease was 100% in control mice and 94.7% in parp-1o/o mice. In both groups, arthritis developed rapidly, the signs of disease appearing as soon as three to five days after the injection of antibody, and reached maximum severity around day seven to nine. PARP-1 deficient mice consistently displayed significantly lower severity of arthritis than parp-1+control mice (p = 0.03 by repeated measures 1-way ANCOVA test) all through the follow-up (Figure 2b).
###end p 34
###begin p 35
These results suggest that PARP-1 has a role in the pathogenesis of this arthritis model.
###end p 35
###begin p 36
###xml 3 9 3 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 9 13 9 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 23 27 23 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
As parp-1+/+ and parp-1+/o control mice had similar clinical phenotypes, for further analysis, they were pooled together and considered as parp-1+.
###end p 36
###begin title 37
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Reduced histological features of joint inflammation and cartilage damage in PARP-1 deficient mice
###end title 37
###begin p 38
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 137 141 137 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 154 156 154 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 464 468 464 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 485 491 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 491 492 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 512 513 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 561 563 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
To quantify joint involvement, we assessed synovial inflammation in H&E stained sections of knee joints. Joints were taken from 14 parp-1o/o and 13 parp-1+ mice on days 5, 7 and 12, and histological sections were scored by two blinded observers on a 0 to 3 scale, corresponding to the degree of thickening of the synovial lining, sublining infiltration and pannus formation. On this scale, we observed a clear trend to a lower synovial inflammation score in parp-1o/o mice compared to parp-1+mice (Figures 3 and 4), although the difference was not significant (p = 0.058, by 1-way MANCOVA fixed effects test).
###end p 38
###begin p 39
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 172 176 172 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 272 274 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 460 464 460 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 468 474 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 474 476 474 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 498 500 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
Joint sections were also stained with Toluidine blue, Safranin-O and Masson trichrome to evaluate cartilage damage. The results also showed a trend to less damage in parp-1o/o mice (Figures 3 and 5), although, again, the difference did not reach statistical significance (p = 0.053, by 1-way MANCOVA fixed effects test). When we considered synovial inflammation and cartilage damage jointly as two facets of the arthritic lesions, the difference between parp-1o/o and parp-1+ mice was significant (p = 0.03).
###end p 39
###begin p 40
Thus, PARP-1 protein appeared to be involved in the pathogenesis of the CAIA model, both in synovial inflammation and cartilage damage, although it did not seem to have a pivotal role.
###end p 40
###begin p 41
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 707 711 707 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 723 729 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 729 731 729 731 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 782 784 782 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
It has been previously described that, in several rodent models of inflammation, PARP-1 activation is involved in neutrophil recruitment [25]. Neutrophils have been implicated in arthritis disease; specifically, extensive neutrophil exudate is displayed in CAIA model [23] and neutrophils release elastase and proteases, which degrade proteoglycans [4]. It remains possible that the decreased severity of arthritis observed in PARP-1 deficient mice was associated with reduced neutrophil exudate in joints from these mice. To evaluate this possibility, we assessed, at five and seven days, the exudate score on a 0 to 3 scale in H&E stained sections of knee joints. Exudate appeared slightly lower in parp-1o/o compared to parp-1+ mice, although the difference was not significant (p = 0.12, by 1-way MANCOVA fixed effects test) (Figure 6). Thus, lack of PARP-1 does not impair neutrophil exudation in this arthritis model.
###end p 41
###begin title 42
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Expression levels of inflammatory mediators in arthritic joints from PARP-1 deficient and sufficient mice
###end title 42
###begin p 43
###xml 447 453 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 453 457 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 461 467 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 467 469 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 493 494 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 653 659 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 659 663 649 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 685 691 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 691 693 681 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 751 757 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 757 761 747 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 773 779 763 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 779 781 769 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 797 799 787 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 822 824 812 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 945 947 931 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 957 959 943 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 996 998 982 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 1124 1125 1110 1111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1304 1310 1290 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 1310 1314 1296 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 791 795 <span type="species:ncbi:10090">mice</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
###xml 1247 1251 <span type="species:ncbi:10090">mice</span>
###xml 1314 1318 <span type="species:ncbi:10090">mice</span>
To explore the possible mechanisms underlying the reduced arthritis observed in PARP-1 knockout mice compared to control mice, we studied, by quantitative real-time PCR, mRNA levels of IL-1beta, IL-6, TNF-alpha, MCP-1, small inducible cytokine A5 (Cc15; RANTES), inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in arthritic joints at day seven after Arthrogen injection. The fold change in mRNA of arthritic versus non-arthritic parp-1o/o and parp-1+ mice is shown in Figure 7. All the inflammatory mediators were detected in both groups of mice and, interestingly, IL-1beta and MCP-1 mRNA were significantly less induced in arthritic parp-1o/o compared to arthritic parp-1+ mice. IL-6 mRNA showed a trend towards lower induction in parp-1o/o compared to parp-1+ arthritic mice (p = 0.1, by Mann-Whitney U test). However, mRNA expression of TNF-alpha and Ccl5 were induced to a similar extend in both groups of arthritic mice (p = 0.9 and p = 0.7, respectively, by Mann-Whitney U test). Transcription of genes encoding iNOS and COX-2, which are involved in the synthesis of nitric oxide and prostaglandin E2, respectively, were induced to levels that were not significantly different in PARP-1 deficient and sufficient arthritic mice. However, a tendency towards lower induction in the parp-1o/o mice was noted.
###end p 43
###begin p 44
###xml 194 200 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 200 204 190 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 226 232 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 232 234 222 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 247 248 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 348 350 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 360 362 346 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 399 401 385 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
To confirm these findings, we next determined the levels of IL-1beta, IL-6, TNF-alpha and MCP-1 proteins in joint tissues. IL-1beta and MCP-1 were significantly reduced in joints from arthritic parp-1o/o compared to arthritic parp-1+ mice (Figure 8); however, there was no difference in the production of TNF-alpha and IL-6 in both groups of mice (p = 0.4 and p = 0.3, respectively, by Mann-Whitney U test). These results are consistent with those obtained for the mRNA analysis.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
###xml 736 741 <span type="species:ncbi:9606">human</span>
Previous studies using genetically engineered animals and pharmacological inhibitors have implicated PARP-1 in the pathogenesis of several inflammatory processes [13-16]. In the present report, we have investigated the impact of selective PARP-1 suppression in the CAIA model and found that absence of PARP-1 protein reduces the severity of disease, likely by the impairment of IL-1beta and MCP-1 transcription in joint tissues. In the arthritis model used, disease develops in most mice strains, avoiding multiple breeding into arthritis susceptible strains. Using a suitable antibody dose, arthritis incidence rises to 100% in control animals and the clinical severity and histopathology are similar to collagen-induced arthritis and human RA. Given the involvement of PARP-1 in inflammation, we considered that it could have a role in the effector phase of arthritis; the CAIA model specifically reflects this phase.
###end p 46
###begin p 47
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
PARP-1 deficient mice had decreased severity in clinical and histological arthritis, although the incidence of disease was similar in control and deficient mice. This is in line with its described involvement in other inflammatory diseases, but with milder effect in the case of arthritis.
###end p 47
###begin p 48
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 577 581 577 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 585 591 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 591 593 591 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 803 810 803 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1 </italic>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
PARP-1 belongs to a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain (for reviews, see [26,27]). PARP-1 catalyzes 80% of cellular poly(ADPribosyl)ation and the other PARP family members, PARP-2, PARP-3, PARP-4 and Tankyrases (PARP-5 a and b), all identified in the last few years, account for the remaining 20%. Therefore, it is possible that when PARP-1 is absent from development, other PARP family members with poly(ADPribosyl)ation activity could compensate for its absence. To evaluate this possibility, we treated parp-1o/o and parp-1+ mice with 3,4-dihydro-5- [4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone (DPQ), one of the new potent PARP inhibitors developed. After treatment, we found similar protection to that observed in mice lacking the parp-1 gene (data not shown), suggesting that PARP-1 is the member of the PARP proteins involved in arthritis inflammation.
###end p 48
###begin p 49
###xml 129 130 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 214 215 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
Our results contrast with the significantly reduced incidence and severity of collagen induced arthritis in mice treated with INH2BP, a PARP inhibitor, reported by Szabo and colleagues [28]. It is possible that INH2BP has effects other than the inhibition of PARP function, because we did not observe such a strong effect with knockout mice, nor with the DPQ inhibitor. Nevertheless, this discordance could also be attributed to either differences in the arthritis model or differences in the inhibitors. In fact, it has been recently shown that another PARP inhibitor, PJ34, reduces the severity rather than incidence of collagen induced arthritis [16].
###end p 49
###begin p 50
###xml 96 97 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 98 99 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 100 101 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 244 246 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 362 364 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 560 562 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 563 565 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 739 741 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 209 215 <span type="species:ncbi:10090">murine</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 491 498 <span type="species:ncbi:9606">patient</span>
###xml 550 558 <span type="species:ncbi:9606">patients</span>
IL-1beta is one of the major cytokines in arthritis driving inflammation and joint destruction [2,4,7]. It has been reported that systemic administration of IL-1 accelerates and exacerbates the development of murine collagen induced arthritis [29], while IL-1 receptor antagonist-deficient mice (BALB/c background) develop chronic polyarthropathy resembling RA [30]. MCP-1 is a potent chemoattractant for monocytes. It seems to be involved in RA pathogenesis because it has been detected in patient sera and found at increased levels in FLSs from RA patients [31-33]. It has been recently reported that MCP-1 induces FLS proliferation, which is pivotal in pannus formation, and increases metalloproteinase production mediated by IL-1beta [34].
###end p 50
###begin p 51
###xml 89 93 <span type="species:ncbi:10090">mice</span>
Thus, the strong reduction in IL-1beta and MCP-1 production observed in PARP-1 deficient mice may account for the reduced severity of arthritis, though signals of a more widespread effect are reflected in the tendency towards the decreased expression of other inflammatory mediators, such as IL-6, iNOS and COX-2.
###end p 51
###begin p 52
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 446 448 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
In contrast to what has been described in the shock endotoxic model [13,16], we did not find impaired TNF-alpha production in mice lacking PARP-1. This could indicate that the requirements of PARP-1 for transcription of inflammatory genes depend on the tissue and the nature of the inflammatory stimulus. In fact, studies with a PARP inhibitor have shown an inhibitory or neutral effect on IL-1beta levels depending on the model of inflammation [16].
###end p 52
###begin title 53
Conclusion
###end title 53
###begin p 54
###xml 227 232 <span type="species:ncbi:9606">human</span>
Overall, our results indicate that PARP-1 plays a role in arthritis progression, probably through impaired IL-1beta and MCP-1 production in joints. Although further investigations are required to evaluate PARP-1 involvement in human RA, this enzyme might be considered as a new target for experimental treatment.
###end p 54
###begin title 55
Abbreviations
###end title 55
###begin p 56
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
CAIA = collagen antibody-induced arthritis; Ccl5 (RANTES) = small inducible cytokine A5; COX-2 = cyclooxygenase; DMEM = Dulbecco's modified Eagle's medium; DPQ = 3,4-dihydro-5- [4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone; FLS = fibroblast-like synoviocyte; H&E = hematoxylin and eosin; IL = interleukin; iNOS = inducible nitric oxide synthase; MCP = monocyte chemotactic protein; NF = nuclear factor; PARP = poly(ADP-ribose) polymerase; RA = rheumatoid arthritis; TNF = tumor necrosis factor.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The authors declare that they have not competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
SG carried out the arthritis evolution, FLS isolation and western blot experiments and quantitative real time PCR analysis. AB carried out the breeding of mice, the arthritis evolution experiments and joint isolation. AG carried out the intravenous injections in mice, performed the statistical analysis, participated in the design of the study and revision of the manuscript. JF carried out the histological scoring. GJ participated in the design and coordination of the study and revision of the manuscript. CC conceived of the study, participated in its design and coordination and drafting of the manuscript. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 450 457 <span type="species:ncbi:558547">Gallego</span>
We thank Dr G de Murcia and Dr J Menissier de Murcia for critical review of this manuscript and for providing the PARP-1 deficient mice and anti-PARP-1 antibody (VIC-5). Supported by Fondo de Investigacion Sanitaria (FIS), Instituto de Salud Carlos III (Spain), grants 01/3054, 02/0490 and G03/152 and by grants from DXID (Xunta de Galicia). AB is supported by FIS (02/0490) and CC is recipient of a research contract from FIS (01/3054) and Servicio Gallego de Salud (SERGAS).
###end p 62
###begin article-title 63
Rheumatoid arthritis
###end article-title 63
###begin article-title 64
Evolving concepts of rheumatoid arthritis
###end article-title 64
###begin article-title 65
Homing chemokines in rheumatoid arthritis
###end article-title 65
###begin article-title 66
Cytokine pathways and joint inflammation in rheumatoid arthritis
###end article-title 66
###begin article-title 67
Rheumatoid arthritis: regulation of synovial inflammation
###end article-title 67
###begin article-title 68
The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover
###end article-title 68
###begin article-title 69
The role of TNF alpha and IL-1 in rheumatoid arthritis
###end article-title 69
###begin article-title 70
An update on the cytokine network in rheumatoid arthritis
###end article-title 70
###begin article-title 71
###xml 53 58 <span type="species:ncbi:9606">human</span>
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
###end article-title 71
###begin article-title 72
Treatment of rheumatoid arthritis with IL-1 inhibitors
###end article-title 72
###begin article-title 73
Poly(ADP-ribose) polymerase: a molecular nick-sensor
###end article-title 73
###begin article-title 74
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?
###end article-title 74
###begin article-title 75
###xml 124 128 <span type="species:ncbi:10090">mice</span>
Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly(ADP-ribose) polymerase-1 deficient mice
###end article-title 75
###begin article-title 76
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin
###end article-title 76
###begin article-title 77
###xml 115 121 <span type="species:ncbi:10090">murine</span>
Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis
###end article-title 77
###begin article-title 78
Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-ribose) polymerase
###end article-title 78
###begin article-title 79
Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion
###end article-title 79
###begin article-title 80
The sequence-specific DNA binding of NF-kappaB is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1
###end article-title 80
###begin article-title 81
A role of poly(ADP-ribose) polymerase in NF-kappaB transcriptional activation
###end article-title 81
###begin article-title 82
Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia
###end article-title 82
###begin article-title 83
###xml 77 83 <span type="species:ncbi:10090">murine</span>
Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts
###end article-title 83
###begin article-title 84
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
###end article-title 84
###begin article-title 85
Induction of arthritis with monoclonal antibodies to collagen
###end article-title 85
###begin article-title 86
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice
###end article-title 86
###begin article-title 87
Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects
###end article-title 87
###begin article-title 88
The PARP superfamily
###end article-title 88
###begin article-title 89
Physiology and pathophysiology of poly(ADP-ribosyl)ation
###end article-title 89
###begin article-title 90
Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase
###end article-title 90
###begin article-title 91
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice
###end article-title 91
###begin article-title 92
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
###end article-title 92
###begin article-title 93
Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis
###end article-title 93
###begin article-title 94
Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes
###end article-title 94
###begin article-title 95
Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium
###end article-title 95
###begin article-title 96
###xml 163 171 <span type="species:ncbi:9606">patients</span>
CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients
###end article-title 96
###begin title 97
Figures and Tables
###end title 97
###begin p 98
###xml 65 69 65 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 300 304 300 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 310 311 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 315 319 315 319 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 325 329 325 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 414 420 414 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 420 422 420 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 468 472 468 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 585 589 585 589 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 589 595 589 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 595 597 595 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 601 605 601 605 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 605 611 605 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 611 615 611 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
Poly(ADP-ribose) polymerase (PARP)-1 expression in joint tissue. (a) Western blot analysis of PARP-1 and actin proteins in fibroblast-like synoviocyte extracts of the indicated genotypes; 100 ng of purified PARP-1 was the control. Immunostaining for PARP-1 expression in the knee joint sections from (b) parp-1+and (d) parp-1o/o mice. Staining for nuclear PARP-1 showed clear immunopositivity on chondrocytes from parp-1+ mice (arrows) whereas chondrocytes from parp-1o/o (arrowheads) remained negative. Negative control staining, by omitting the primary antibody, in knee joints from (c) parp-1+ and (e) parp-1o/o mice.
###end p 98
###begin p 99
###xml 169 173 169 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 223 225 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 249 253 249 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 274 278 274 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 318 321 318 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 331 335 331 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 348 352 348 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 456 458 454 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 466 472 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 472 476 470 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 480 486 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 486 490 484 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/o </sup>
###xml 497 503 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 503 507 501 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
Reduced severity of arthritis in poly(ADP-ribose) polymerase (PARP)-1 deficient mice and PARP-1 sufficient mice following collagen antibody-induced arthritis induction. (a) Representative pictures of arthritis in the parp-1+ (left panels) and parp-1o/o (right panels) mice. (b) Clinical score was measured in 18 parp-1+/+, 8 parp-1+/o and 19 parp-1o/o mice from day 5 to day 12 after injection. Values are expressed as mean +/- standard error of the mean; p = 0.03, parp-1+/+ and parp-1+/o versus parp-1o/o mice, by ANCOVA test.
###end p 99
###begin p 100
###xml 156 160 156 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 186 190 186 190 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 249 255 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 255 259 255 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 397 399 395 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 407 413 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 413 415 411 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 422 428 420 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 428 432 426 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
Milder synovial inflammation and cartilage damage in poly(ADP-ribose) polymerase (PARP)-1 deficient mice than in control mice. Histopathological scoring of (a) synovial inflammation and (b) cartilage damage of knee joint sections of parp-1+mice and parp-1o/o mice at day 5 and 12 after induction of collagen antibody-induced arthritis. Values are expressed as mean +/- standard error of the mean; p = 0.03, parp-1+ versus parp-1o/o mice by combined analysis of (a) and (b) (MANCOVA test).
###end p 100
###begin p 101
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 275 279 275 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 289 293 289 293 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 339 343 339 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 351 355 351 355 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 365 369 365 369 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
Representative hematoxylin-eosin stained sections of knee joints in mice with collagen antibody-induced arthritis (CAIA). Severe inflammation, pannus formation and associated cartilage destruction were observed in sections stained with hematoxylin-eosin from parp-1+ mice at (a) day 5 and (b) day 12 after CAIA induction compared to parp-1o/o mice at (c) day 5 and (d) day 12.
###end p 101
###begin p 102
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 228 232 228 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 242 246 242 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 305 309 305 309 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 319 323 319 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
Representative sections stained with Safranin O in mice with collagen antibody-induced arthritis (CAIA). More severe loss of proteoglycans, indicated by destained cartilage layers, were observed in sections from parp-1+ mice at (a) day 5 and (b) day 12 after CAIA induction compared with knockout mice at (c) day 5 and (d) day 12.
###end p 102
###begin p 103
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 71 75 71 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 179 183 179 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 337 343 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 343 344 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 348 354 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 354 358 352 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 399 401 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
Comparable exudate scores in the arthritic joints of parp-1+ and parp-1o/o mice. Exudate score was evaluated in knee sections stained with hematoxylin-eosin from parp-1+and parp-1o/o mice at day 5 and 7 after induction of collagen antibody-induced arthritis. Values represent the mean +/- standard error of the mean. Differences between parp-1+and parp-1o/o mice were not statistically significant (p = 0.12 by 1-way MANCOVA test).
###end p 103
###begin p 104
###xml 363 369 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 369 371 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 375 381 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 381 385 371 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 566 572 554 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 572 574 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 578 584 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 584 588 572 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 657 659 642 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 698 700 683 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 725 727 710 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
Reduced IL-1beta and monocyte chemotactic protein (MCP)-1 mRNA levels in mice lacking poly(ADP-ribose) polymerase (PARP)-1. IL-1beta, MCP-1, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, tumor necrosis factor (TNF)-alpha, IL-6 and small inducible cytokine A5 (Ccl5) mRNA levels were measured by quantitative real-time PCR in arthritic joints of parp-1+ and parp-1o/o mice at day 7 after induction of collagen antibody-induced arthritis. Values are expressed as mean +/- standard error of the mean of six to nine mice per group. Differences between parp-1+ and parp-1o/o mice were statistically significant for IL-1beta (asterisk indicates p = 0.005) and MCP-1 (asterisk indicates p = 0.004) by Mann-Whitney U test.
###end p 104
###begin p 105
###xml 455 461 443 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 461 463 449 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 467 473 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parp-1</italic>
###xml 473 477 461 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">o/o </sup>
###xml 546 548 531 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 586 588 571 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 612 614 597 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
Reduced IL-1beta and monocyte chemotactic protein (MCP)-1 levels in arthritic joints of mice lacking poly(ADP-ribose) polymerase (PARP)-1. Levels of IL-1beta, tumor necrosis factor (TNF)-alpha, IL-6 and MCP-1 were measured by ELISA in extracts from arthritic knee joints of mice at day 7 after induction of collagen antibody-induced arthritis. Values are expressed as mean +/- standard error of the mean of six to nine mice per group. Differences between parp-1+ and parp-1o/o mice were statistically significant for IL-1beta (asterisk indicates p = 0.03) and MCP-1 (asterisk indicates p = 0.05) by Mann-Whitney U test.
###end p 105
###begin p 106
Primer sets used for quantitative PCR study
###end p 106

